Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761929 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL12161594 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL131620 | 0.77 | GPR35 (0.57) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL31215172 | 0.77 | GPR35 (0.57) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL30890603 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL126405 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL541340 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL1507262 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL307869 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E | |
| SCHEMBL30230648 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRCYP3A4GPR35KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TAXIS PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| EP-3345899-B1 | BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3345899-B1 | BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3345899-A1 | BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345899-A1 | BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2820010-B1 | BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2820010-B1 | BENZOFURAN-2-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180002347-A1 | CONDENSED HETEROCYCLIC COMPOUND HAVING CYCLOALKYLPYRIDYL GROUP OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE INSECTICIDE | NIHON NOHYAKU CO., LTD. (JP) | 2018-01-04 | — | — | US | disclosed |
| US-9416120-B2 | Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416120-B2 | Benzofuran-2-sulfonamides pyridine derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-8742112-B2 | Heterocyclic compound and its use for control of an arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| WO-2013130962-A1 | BENZOFURAN- 2 - SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130962-A1 | BENZOFURAN- 2 - SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130231339-A1 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231339-A1 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231339-A1 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-0618209-B1 | Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1998-12-23 | — | — | EP | disclosed |
| US-5459138-A | Dysfunctions of glutamatergic neurotransmission associated with learning and memory | ADIR ET COMPAGNIE (FR) | 1995-10-17 | — | — | US | disclosed |
| EP-0618209-A1 | Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231339-A1 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CCR2, CXCR2, CXCR4 | SMN1; SMN2 3781/4885TSHR 902/4885CYP3A4 1718/4885 |
| US-20230257397-A1 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | TXN, TBXAS1, TXK | SMN1; SMN2 3456/4885TSHR 316/4885CYP3A4 367/4885 |
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | HAAO, DDT, ACHE | SMN1; SMN2 1085/4885TSHR 228/4885CYP3A4 138/4885 |
| US-20180002347-A1 | CONDENSED HETEROCYCLIC COMPOUND HAVING CYCLOALKYLPYRIDYL GROUP OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE INSECTICIDE | DDT, HCN3, HCN1 | SMN1; SMN2 3421/4885TSHR 3062/4885CYP3A4 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.